Pharsight

Vyzulta patents expiration

VYZULTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6211233 BAUSCH AND LOMB Prostaglandin pharmaceutical compositions
Jun, 2018

(6 years ago)

US7910767 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(6 months from now)

US7273946 BAUSCH AND LOMB Prostaglandin derivatives
Oct, 2025

(1 year, 3 months from now)

US8058467 BAUSCH AND LOMB Prostaglandin derivatives
Feb, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7629345 BAUSCH AND LOMB Prostaglandin derivatives
Jan, 2025

(6 months from now)

Vyzulta is owned by Bausch And Lomb.

Vyzulta contains Latanoprostene Bunod.

Vyzulta has a total of 5 drug patents out of which 1 drug patent has expired.

Expired drug patents of Vyzulta are:

  • US6211233

Vyzulta was authorised for market use on 02 November, 2017.

Vyzulta is available in solution/drops;ophthalmic dosage forms.

Vyzulta can be used as reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension.

The generics of Vyzulta are possible to be released after 21 February, 2029.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using LATANOPROSTENE BUNOD ingredient

Market Authorisation Date: 02 November, 2017

Treatment: Reduction of intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of VYZULTA before it's drug patent expiration?
More Information on Dosage

VYZULTA family patents

Family Patents